GlassScriptPhysician profile
Dinesh Madhok
NPI 1366434409
$10,346.88
in general payments reported to CMS, 2019-2025
36 companies · $1,552 in 2025
The $1,552 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,344 · 2020: $459 · 2021: $1,152 · 2022: $1,457 · 2023: $2,146 · 2024: $2,237 · 2025: $1,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,921 · Education: $13.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,921.20 |
| Education | $13.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,129.38 | 2019-2025 | |
| Janssen Biotech, INC. | $1,164.39 | 2019-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $953.70 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $892.71 | 2019-2025 | Entyvio, Gattex |
| Genzyme Corporation | $458.73 | 2022-2025 | |
| Celgene Corporation | $391.21 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $334.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $279.29 | 2023-2025 | Omvoh |
| Olympus America INC. | $278.09 | 2019-2024 | Evis X1 Video System Center |
| Gilead Sciences, INC. | $251.72 | 2019-2025 | |
| Pfizer INC. | $247.63 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $243.47 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $195.43 | 2019-2024 | Linzess |
| Merck Sharp & Dohme LLC | $192.37 | 2019-2024 | Dificid |
| Aimmune Therapeutics, INC. | $173.58 | 2024-2025 | Zenpep |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $125.70 | 2019-2024 | Suflave, Sutab |
| Medtronic, INC. | $109.91 | 2021-2025 | Interstim |
| Ipsen Biopharmaceuticals, INC | $101.03 | 2025 | Iqirvo |
| Vivus LLC | $100.37 | 2021-2024 | Qsymia |
| Phathom Pharmaceuticals, INC. | $85.45 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $80.26 | 2021-2022 | |
| Qol Medical, LLC | $75.28 | 2021-2025 | Sucraid, Sucraid |
| Shionogi INC | $73.23 | 2019 | |
| Ferring Pharmaceuticals INC. | $59.59 | 2022-2023 | Rebyota |
| Alnylam Pharmaceuticals INC. | $50.52 | 2021-2023 | Givlaari |
| Intercept Pharmaceuticals, INC. | $48.12 | 2019-2023 | Ocaliva |
| Redhill Biopharma INC. | $38.29 | 2021 | |
| Allergan, INC. | $35.21 | 2019-2020 | |
| Ardelyx, INC. | $35.00 | 2023-2024 | Ibsrela |
| Celltrion USA INC. | $28.60 | 2024-2025 | Vegzelma, Zymfentra |
| Concordia Pharmaceuticals INC. | $26.05 | 2019 | |
| Pharmacosmos Therapeutics INC. | $22.65 | 2023 | Monoferric |
| Phadia US INC. | $19.96 | 2019 | |
| Daiichi Sankyo INC. | $19.39 | 2024 | Injectafer |
| Amgen INC. | $14.28 | 2025 | Uplizna |
| Alfasigma USA, INC. | $11.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dinesh Madhok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.